Genta Announces Second Quarter 2008 Financial Results and Conference Call

BERKELEY HEIGHTS, N.J., July 31 /PRNewswire-FirstCall/ -- Genta
Incorporated (OTC Bulletin Board: GNTA) announced today that the Company will
release its second quarter 2008 financial results on Thursday, August 7, 2008.
Genta management will host a conference call and live audio webcast to discuss
these financial results and corporate activities at 8:00 am EDT.
Participants can access the live call by dialing (877) 634-8606 (U.S. and
Canada) or (706) 679-3140 (International). The access code for the live call
is Genta Incorporated. The call will also be webcast live at
http://www.genta.com/investorrelation/events.html
For investors unable to participate in the live call, a replay will be
available approximately two hours after the completion of the call, and will
be archived for 30 days. Access numbers for this replay are: (800) 642-1687
(U.S. and Canada) and (706) 645-9291 (International); conference ID number is
57549066.
About Genta
Genta Incorporated is a biopharmaceutical company with a diversified
product portfolio that is focused on delivering innovative products for the
treatment of patients with cancer. Two major programs anchor the Company's
research platform: DNA/RNA-based Medicines and Small Molecules. Genasense(R)
(oblimersen sodium) Injection is the Company's lead compound from its DNA/RNA
Medicines program. Genta is currently recruiting patients to the AGENDA
Trial, a global Phase 3 trial of Genasense in patients with advanced melanoma.
The leading drug in Genta's Small Molecule program is Ganite(R) (gallium
nitrate injection), which the Company is exclusively marketing in the U.S. for
treatment of symptomatic patients with cancer-related hypercalcemia that is
resistant to hydration. The Company has developed G4544, an oral formulation
of the active ingredient in Ganite, that has recently entered clinical trials
as a potential treatment for diseases associated with accelerated bone loss.
The Company is also developing tesetaxel, a novel, orally absorbed,
semi-synthetic taxane that is in the same drug class as paclitaxel and
docetaxel. Ganite and Genasense are available on a "named-patient" basis in
countries outside the United States. For more information about Genta, please
visit our website at: www.genta.com.
Safe Harbor
This press release may contain forward-looking statements with respect to
business conducted by Genta Incorporated. By their nature, forward-looking
statements and forecasts involve risks and uncertainties because they relate
to events and depend on circumstances that will occur in the future.
Forward-looking statements include, without limitation, statements about:
-- the Company's ability to obtain necessary regulatory approval for
Genasense(R) from the U.S. Food and Drug Administration ("FDA") or European
Medicines Agency ("EMEA");
-- the safety and efficacy of the Company's products or product
candidates;
-- the Company's assessment of its clinical trials;
-- the commencement and completion of clinical trials;
-- the Company's ability to develop, manufacture, license and sell its
products or product candidates;
-- the Company's ability to enter into and successfully execute license
and collaborative agreements, if any;
-- the adequacy of the Company's capital resources and cash flow
projections, the Company's ability to obtain sufficient financing to maintain
the Company's planned operations, or the Company's risk of bankruptcy if it is
unsuccessful in obtaining such financing or in securing shareholder approval
to increase the number of shares authorized for issuance under the Company's
certificate of incorporation, as required by the transactional documents in
our recent financing;
-- the adequacy of the Company's patents and proprietary rights;
-- the impact of litigation that has been brought against the Company and
any proposed settlement of such litigation; and
-- the other risks described under Certain Risks and Uncertainties Related
to the Company's Business, as contained in the Company's Annual Report on Form
10-K and Quarterly Report on Form 10-Q.
The Company does not undertake to update any forward-looking statements.
There are a number of factors that could cause actual results and developments
to differ materially. For a discussion of those risks and uncertainties,
please see the Company's Annual Report on Form 10-K for 2007 and its most
recent quarterly report on Form 10-Q.
CONTACT:
Genta Investor Relations
info@genta.com

SOURCE Genta Incorporated

Genta Investor Relations, +1-908-286-3980, or info@genta.com